As analysts unveil their top stock picks for 2020, it’s also worth examining how their top picks for 2019 ended up performing. Today’s article does just that, identifying the top 20 Wall Street picks for 2019 among large-cap, mid-cap and small-cap stocks (based on the number of “buy” or equivalent analyst ratings and implied upside potential at the beginning of the year) and their total returns through mid-December. How did analysts’ stock selections do – and how does this analysis “shed light on one of the problems with Wall Street”? CLICK HERE.
“When there are just a few analysts covering a company, the analysts have a large incentive to deliver high quality and accurate research,” notes the author of today’s article, who further observes that this “means that small companies with favorable research coverage could be stocks that deliver large returns.” Based on this insight, the author screened for low-priced (trading under $5) stocks rated as strong buys by analysts. For the five stocks that passed the screen, and which may be worthy of further consideration, CLICK HERE.
The little-known stock highlighted in today’s article is not cheap based on its current valuation or near-term estimates. And, having more than doubled in the last year, some may question whether it has much more room to run. So why does the author argue there is good reason to believe that Cognex Corporation – operating in the machine-vision space – will beat analyst estimates and “move significantly higher this year”? To read more about Cognex and the multiple growth drivers the author sees for it that may make it an attractive pick, CLICK HERE.
Regardless of which presidential candidate emerges victorious on November 8th, the next administration is expected to provide a significant boost to government spending on infrastructure. While some investors are already starting to make anticipatory plays on this front, the author of today’s article cautions that “investors who want their portfolios to follow the government money should keep in mind a few facts before committing their own cash.” Which specific areas – and specific companies – might be better plays for a Clinton administration, and which might be more lucrative for a Trump administration? How do analysts believe this new domestic infrastructure investment will be different from the last? What kind of time frame should investors have in mind for these plays? CLICK HERE to find out.
“Guns, taxes and drug companies’ profits may incite or even outrage voters. Drug companies’ profits, though, excite investors.” Today’s article highlights the fact that “profits jumped 17.3% at companies in the pharmaceuticals, biotechnology and life sciences tools and services industries in the Standard & Poor’s 500 last year…faster profit growth than any of the 10 major industry sectors….” But with the drug industry and its profits being the target of heated rhetoric in the presidential campaign (including calls for greater regulation), should investors fear a serious threat to the industry’s continued profit growth? To read what analysts have to say, and to see which drug manufacturers posted the fastest-growing profits in 2015, CLICK HERE.